Status:
TERMINATED
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
This study will collect data on safety, effectiveness and patient acceptance of MabCampath treatment under daily life conditions.
Detailed Description
As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer Schering Pharma AG...
Eligibility Criteria
Inclusion
- In- and outpatients suffering from CLL, who are treated with Mab Campath, and are routinely monitored with PCR (Polymerase Chain Reaction) for CMV infection during MabCampath treatment and for at least 2 months following completion of treatment.
Exclusion
- In accordance with Summaries of Product Characteristics (SPC).
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00836043
Start Date
October 1 2008
End Date
April 1 2009
Last Update
December 3 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Bosnia and Herzegovina
2
Many Locations, Israel
3
Many Locations, North Macedonia